JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
76 hedge funds and large institutions have $239M invested in Jounce Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 38 increasing their positions, 10 reducing their positions, and 9 closing their positions.
Holders
76
Holders Change
+4
Holders Change %
+5.56%
% of All Funds
1.9%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
13
Increased
38
Reduced
10
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
PHS
1
PFM Health Sciences
San Francisco,
California
|
$26.9M |
| 2 |
2
BlackRock
New York
|
$11.3M |
| 3 |
3
Vanguard Group
Malvern,
Pennsylvania
|
$9.02M |
| 4 |
CC
4
Casdin Capital
New York
|
$6.23M |
| 5 |
FI
5
Fosun International
Hong Kong,
China
|
$4.46M |
